Meaningful endpoints for therapies approved for hematologic malignancies.

Smith, B Douglas; DeZern, Amy E; Bastian, Alex W; Durie, Brian G M

Smith, B Douglas; DeZern, Amy E; Bastian, Alex W; Durie, Brian G M.

Affiliation

Smith BD; Kimmel Cancer Center/Johns Hopkins, Baltimore, Maryland.
DeZern AE; Kimmel Cancer Center/Johns Hopkins, Baltimore, Maryland.
Bastian AW; GfK Market Access, San Francisco, California.
Durie BGM; Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California.

Cancer ; 123(10): 1689-1694, 2017 05 15.

Article in En | MEDLINE | ID: mdl-28222220

Subject(s)

Antineoplastic Agents/therapeutic use; Disease-Free Survival; Hematologic Neoplasms/drug therapy; Outcome Assessment, Health Care; Survival Rate; Drug Approval; Endpoint Determination; Humans; Proportional Hazards Models; Retrospective Studies; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration

Key words

US Food and Drug Administration; cancer; drug approval; endpoints; hematologic malignancies; medical oncology; overall survival; progression-free survival

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Survival Rate / Outcome Assessment, Health Care / Disease-Free Survival / Hematologic Neoplasms / Antineoplastic Agents Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Cancer Year: 2017 Type: Article

Fulltext

XML

PubMed Links

Search on Google